Zevra Therapeutics, Inc. Severance Costs
Zevra Therapeutics, Inc. (ZVRA) reported Severance Costs of $1.40 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2023-11-07
- Zevra Therapeutics, Inc. severance costs for the quarter ending 2023-09-30 was -$1.00K.
- Zevra Therapeutics, Inc. severance costs for the quarter ending 2023-06-30 was $402.00K.
- Zevra Therapeutics, Inc. severance costs for the quarter ending 2023-03-31 was $1.00M.
- Zevra Therapeutics, Inc. severance costs for the quarter ending 2022-09-30 was $0.00.
- Zevra Therapeutics, Inc. severance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Zevra Therapeutics, Inc. severance costs for fiscal 2020 was $828.00K.
- Zevra Therapeutics, Inc. severance costs for fiscal 2018 was $1.64M.
- Zevra Therapeutics, Inc. severance costs for fiscal 2016 was $3.01M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $401.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.40M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $402.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.40M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $1.00M 10-Q · filed 2023-05-15 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 derived: sum of 3 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | -$2.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | -$2.00K derived: sum of 3 quarters · filed 2022-03-31 | -$2.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-03-31 | -$2.00K derived: sum of 2 quarters · filed 2022-03-31 | -$2.00K derived: sum of 3 quarters · filed 2022-03-31 | -$2.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$2.00K derived: sum of 2 quarters · filed 2022-03-31 | -$2.00K derived: sum of 3 quarters · filed 2022-03-31 | $828.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $830.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $830.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $830.00K 10-Q · filed 2021-05-14 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $1.64M derived: sum of 2 quarters · filed 2020-02-28 | $1.64M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $1.64M 10-Q · filed 2019-11-14 | $1.64M 10-Q · filed 2019-11-14 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $3.01M derived: sum of 2 quarters · filed 2018-03-30 | $3.01M 10-K · filed 2018-03-30 | |
| 2016-09-30 | $3.01M 10-K · filed 2018-03-30 | $3.01M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |